Jack Allen Stock Analyst Profile - Baird Research Coverage - Stocknear

Jack Allen

Stock Analyst at Baird

(3.23)
# 2850
Out of 5,477 analysts
51
Total ratings
Success rate
Average return
Main Sectors:
Top Industries:
19 Stocks
Name Action PT Current % Upside Ratings Updated
VOR Vor Biopharma
Maintains: Neutral
1 1
1.81 -44.75% 4 Jun 27, 2025
FATE Fate Therapeutics
Maintains: Neutral
5 4
1.02 292.16% 2 May 14, 2025
ALLO Allogene Therapeutic...
Maintains: Outperform
12 9
1.17 669.23% 3 May 14, 2025
CARM CARISMA Therapeutics
Downgrades: Neutral
10 1
n/a n/a 3 Dec 12, 2024
INKT MiNK Therapeutics
Maintains: Outperform
80 40
15.04 165.96% 2 Nov 15, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
77 106
77.68 36.46% 5 Nov 6, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
24 18
11.42 57.62% 2 Oct 25, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Outperform
180 180
23.8 656.3% 9 Sep 16, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
140 120
4.97 2314.49% 3 Aug 15, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
8
1.82 339.56% 1 Jun 13, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
46 52
55.89 -6.96% 2 May 9, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
84
36.57 129.7% 1 Oct 31, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
200 25
n/a n/a 3 Sep 26, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
6 8
3.24 146.91% 4 Aug 15, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
21 6
4.91 6.92% 2 Aug 10, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
5
1.3 284.62% 1 Nov 2, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
9
3.2 181.25% 1 Sep 13, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Outperform
n/a
n/a n/a 2 May 18, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Outperform
6 9
4.38 105.48% 1 Oct 7, 2021